Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Drug / Therapy12 Peer-Reviewed Briefings
Antibiotics & Antimicrobials
Targeted antimicrobials, beta-lactamase combinations, and bacteriophage therapies against resistant pathogens.
Active Specialties:NeurologyInfectious DiseasePulmonologyAI in MedicineGastroenterology
This case highlights fulminant cerebellitis as a life-threatening presentation of anti-GABA A R encephalitis and underscores the... She later stabilized with radiographic improvement and meaningful neurologic recovery.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Personalized phage therapy, now backed by international guidelines, is becoming a viable and effective strategy against challenging multidrug-resistant bacterial infections. With antibiotic resistance posing a critical global health threat, these guidelines offer a vital new tool for clinicians.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Risk of death associations with antibiotics beyond 1 hour were most evident when sepsis time zero was defined by hypotension or lactate ≥4.0mmol/L, and with antibiotics beyond 3 hours when defined by acute respiratory failure. These findings could inform refinements to sepsis time zero definitions to better guide antibiotic urgency and performance measurement.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
1 min read·American Journal of Respiratory and Critical Care Medicine·
These results suggest that about a third of adults with cystic fibrosis (tissue scarring) who are treated with ETI had a persistent decline in ppFEV 1 . These data emphasise the importance of regular ppFEV 1 monitoring and highlight the need to improve current therapeutic strategies to prevent ppFEV 1 decline.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Finally, the case provides preliminary evidence supporting combination antiviral therapy in persistent LCMV infection. Molnupiravir was later substituted for favipiravir, and favipiravir dosing was guided by serum and CSF therapeutic drug monitoring.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Imipenem-cilastatin-funobactam is statistically non-inferior to imipenem-cilastatin-relebactam for 14-day all-cause risk of death in patients with HABP and VABP with a favourable safety profile. New antibiotics are urgently needed for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
However, clinical use should be limited to an adjunctive role rather than standalone rule-out decision-making, and prospective studies are required to evaluate safety, clinician uptake, and real-world impact. Decision curve analysis demonstrated positive net benefit across much of the evaluated threshold range.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Over the past 20 years, a decreasing proportion of DILI cases are attributed to antibiotics while an increasing proportion are attributed to HDS products and antineoplastics. Oncology patients and those > 65 years old have significantly higher overall and liver-related risk of death.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Alginate engages a fiber-microbiota-taurine-epithelial signaling pathway that promotes recovery in preclinical models. The clinical trial did not meet its primary endpoint; however, the biological changes warrant further investigation of alginate as a microbiota-targeted intervention.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
We propose a pragmatic framework (≥8 mg/kg per day for E faecium, 10-12 mg/kg per day in vancomycin-resistant disease, MIC-informed dose selection, β-lactam combination in endocarditis, and weekly creatine phosphokinase monitoring) and call for therapeutic drug monitoring, harmonised breakpoints, prospective studies, and molecular resistance detection. Any-grade creatine phosphokinase elevation rises modestly with dose in the largest registry but is inconsistent elsewhere, with a clearer signal of marked elevation at the highest doses.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Patients' individual characteristics modified the effect of cefepime versus piperacillin-tazobactam on survival without acute kidney injury but not on survival without delirium or coma. Among adults hospitalized with acute infection, a recent randomized trial observed no significant average treatment effect of cefepime versus piperacillin-tazobactam on acute kidney injury or death, but fewer days-alive-and-free-of delirium and coma with cefepime.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min read·American Journal of Respiratory and Critical Care Medicine·
Hospitalisation, regardless of country, is characterised by loss of short-chain fatty acid-producing taxa, functional shifts, ARG and pathway changes. Gut microbiome composition and function are associated with short-term hospitalisation risk and provide additional prognostic information beyond clinical variables in a multicountry cohort.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
1 min read·Gut·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”